Double Bond Pharmaceutical International AB

Redeveloping drugs with proprietary delivery tech for oncology & infectious diseases.

DBP B | SPGR

Overview

Corporate Details

ISIN(s):: SE0007185517 (+1 more)
LEI:: 254900U1MWE2YSPREX74
Country:: Sweden
Address:: Virdings Alle 32B, 754 50 Uppsala
Website:: https://www.doublebp.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Double Bond Pharmaceutical International AB is a pharmaceutical company specializing in the redevelopment of established drugs to improve their safety and efficacy. The company's strategy centers on applying its proprietary drug delivery technologies to create new formulations of proven medications. Its key platforms include BeloGal®, a biomimetic encapsulation system that enables targeted delivery of active ingredients to specific organs, and an innovative hydrogel for localized treatment. This approach aims to enhance therapeutic effects while minimizing systemic toxicity. The company's pipeline focuses on areas with significant unmet medical needs, such as oncology and infectious diseases. Lead candidates include SI-053 for glioblastoma (brain cancer), SA-033 for liver cancer, and Belopenem for pneumonia.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Double Bond Pharmaceutical International AB filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Double Bond Pharmaceutical International AB via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
2cureX AB Predicts cancer drug response using 3D tumoroid tests to guide personalized oncology.	Sweden	2CUREX
4BASEBIO PLC Manufactures GMP-compliant synthetic DNA for advanced therapies, vaccines, and cell/gene therapies.	United Kingdom	4BB
4SC AG Developing small-molecule epigenetic drugs for high-need cancer indications.	Germany	VSC
Abera Bioscience AB Develops next-gen mucosal vaccines using its OMV platform, with a lead pneumococcal candidate.	Sweden	ABERA
ABINGDON HEALTH PLC A CDMO for lateral flow rapid tests, providing end-to-end services and its own branded products.	United Kingdom	ABDX
ABIONYX Pharma Biotech developing lipid-based therapies for rare renal and ophthalmological diseases.	France	ABNX
Abliva Develops clinical-stage medicines for rare primary mitochondrial diseases to restore cell function.	Sweden	ABLI
AB Science Develops protein kinase inhibitors for oncology, neuro, and inflammatory diseases.	France	AB
Access Bio, Inc. Develops and manufactures rapid diagnostic tests for infectious diseases for global health.	United States of America	950130
Active Biotech Develops immunology-based drugs for cancer and inflammatory diseases with high unmet medical need.	Sweden	ACTI